JCO oncology practice 2023 Jun 07
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
Related Questions
New answer by Medical Oncologist at Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty (July 5, 2025)
Current evidence indicates that Dato-DXd demonstrates promising PFS and manageable toxicity in heavily pretreated HR+/HER2- patients, but network meta-analyses suggest it may ...